Skip to main content

Advertisement

SpringerLink
Log in

Botulinum Toxin therapy for myofascial pain disorders

  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Myofascial pain disorder can originate from various muscles in the body. Numerous therapeutic approaches have been used to treat myofascial pain syndrome with varying success. Botulinum toxin neurolysis may become an important treatment regimen because it sustains relaxation of muscles. There is a growing body of clinical evidence for the efficacy of botulinum toxin in the treatment of painful myofascial conditions. The conditions that have been investigated include chronic low back pain, chronic cervical-associated headache, myofascial pain, myofascial pain syndrome and pain from chronic muscle spasm, and refractory myofascial pain. One of these studies was an open-label, exploratory pilot study into the cervicothoracic and lumbosacral regions using a novel injection technique.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Purdue Pharma LP: A Survey of Pain in America. http://www.purduepharma. com/html/partners_pain/partners_against pain.htm. Accessed June, 2001.

  2. RubinR:Powerful painkillers: a reprieve for patients but a conlict for doctors. USA Today August 9, 2001.

  3. Bonica JJ: The Management of Pain, edn 2. Philadelphia: Lea and Febiger; 1990.

    Google Scholar 

  4. Yazici Y, Gibofsky Y: A diagnostic approach to musculoskeletal pain. Clin Cornerstone 1999, 2(2):1–7.

    Article  PubMed  CAS  Google Scholar 

  5. Odergren T, Tollback A, Borg J: Efficacy of botulinum toxin for cervical dystonia: a comparison of methods for evaluation. Scand J Rehabil Med 1994, 26(4):191–195.

    PubMed  CAS  Google Scholar 

  6. Greene P, Kang U, Fahn S, et al.: Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990, 40(8):1213–1218.

    PubMed  CAS  Google Scholar 

  7. Brin MF, Fahn S, Moskowitz C, et al.: Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. In Advances in Neurology. Edited by Fahn S. Dystonia 2. New York: Raven Press; 1988: 50:599–608.

  8. Tsui JKC, Fross RD, Calne S, Calne DB: Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci 1987, 14(3 Suppl):533–535.

    PubMed  CAS  Google Scholar 

  9. Polo KB, Jabbari B: Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin. Mov Disord 1994, 9(2):233–235.

    Article  PubMed  CAS  Google Scholar 

  10. Barwood S, Baillieu C, Boyd R, et al.: Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol 2000, 42(2):116–121.

    Article  PubMed  CAS  Google Scholar 

  11. Smuts JA, Baker MK, Smuts HM, et al.: Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol 1999, 6(Suppl 4):S99-S102.

    Google Scholar 

  12. Freund BJ, Schwartz M: Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache 2000, 40(3):231–236.

    Article  PubMed  CAS  Google Scholar 

  13. Filippi GM, Errico P, Santarelli R, et al.: Botulinum A toxin effects on rat jaw muscle spindles. Acta Oto-Laryngol 1993, 113(3):400–404.

    CAS  Google Scholar 

  14. Rosales RL, Arimura K, Takenaga S, Osame M: Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996, 19(4):488–496.

    Article  PubMed  CAS  Google Scholar 

  15. Moreno-Lopez B, De la Cruz RR, Pastor AM, Delgado-Garcia JM: Botulinum neurotoxin alters the discharge characteristics of abducens motoneurons in the alert cat. J Neurophysiol 1994, 72(4):2041–2044.

    PubMed  CAS  Google Scholar 

  16. Priori A, Berardelli A, Mercuri B, Manfredi M: Physiologic effects produced by botulinum toxin treatment of upper limb dystonia: changes in reciprocal inhibition between forearm muscles. Brain 1995, 118(3):801–807.

    Article  PubMed  Google Scholar 

  17. Purkiss J, Welch M, Doward S, Foster K: Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000, 59(11):1403–1406.

    Article  PubMed  CAS  Google Scholar 

  18. Welch MJ, Purkiss JR, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38(2):245–258.

    Article  PubMed  CAS  Google Scholar 

  19. Ishikawa H, Mitsui Y, Yoshitomi T, et al.: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000, 44(2):106–109.

    Article  PubMed  CAS  Google Scholar 

  20. Cui M, Khanijou S, Rubino J, Aoki KR: Botulinum toxin A inhibits the inflammatory pain in the rat formalin model [abstract]. Soc Neurosci Abstr 2000, 26(1-2).

  21. Foster L, Clapp L, Erickson M, Jabbari B: Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 2001, 56(10):1290–1293. This study evaluated the efficacy of botulinum toxin type A (BTX-A) in the treatment of chronic low back pain. At week 3, BTX-A was superior to placebo (VAS, P = 0.012), and at week 8, BTX-A was superior to placebo (VAS, P = 0.009 and OLBPQ, P = 0.011).

    PubMed  CAS  Google Scholar 

  22. Porta M: A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000, 85(1-2):101–105.

    Article  PubMed  CAS  Google Scholar 

  23. Lang AM: A pilot study of botulinum toxin type A (BOTOX), administered using a novel injection technique, for the treatment of myofascial pain: preliminary findings. Am J Pain Manage 2000, 10(3):108–112. This study describes a novel injection technique using botulinum toxin type A. It was an open-label, exploratory pilot study into the cervicothoracic and lumbosacral regions using this injection technique.

    Google Scholar 

  24. Royal MA, Gunyea I, Bhakta B, et al.: Botulinum toxin type A in the treatment of refractory myofascial pain. Neurology 2001, 56(Suppl 3):A350.

    Google Scholar 

  25. Freund BJ, Schwartz M: Treatment of chronic cervical-associate headache with botulinum toxin: a pilot study. Headache 2000, 40(3):231–236.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. OrthoREHAB Plus, P.C., 575 Professional Drive, Suite 250, 30045, Lawrenceville, GA, USA

    Amy M. Lang MD

Authors
  1. Amy M. Lang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lang, A.M. Botulinum Toxin therapy for myofascial pain disorders. Current Science Inc 6, 355–360 (2002). https://doi.org/10.1007/s11916-002-0076-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-002-0076-8

Keywords

Search

Navigation